How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

500 results for

Unintentional Weight Loss Causes

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

481. Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

progression with either of the following manifestations: Moderate-severe right upper quadrant pain and unintentional weight loss > 10% Decline in Karnofsky performance status > 10 points At least a 20% increase in the sum of the longest diameters of target lesions in the liver within the past 12 months No more than 75% replacement of normal liver by neuroendocrine tumor No more than 20% arteriovenous lung shunting on a technetium Tc 99m macro-aggregated albumin nuclear scan No equivocal, nonmeasurable (...) , 2012 Sponsor: Vanderbilt-Ingram Cancer Center Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Steven Meranze, MD, Vanderbilt-Ingram Cancer Center Study Details Study Description Go to Brief Summary: RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well internal radiation therapy works

2007 Clinical Trials

482. Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: histologic or cytologic proof of single primary non-small cell lung cancer No prior chemotherapy or radiation therapy no prior malignancy Exclusion Criteria: pregnancy or breastfeeding serious concomitant systemic disorder unintentional weight loss greater than 10% Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may (...) Survival [ Time Frame: 2 years ] Secondary Outcome Measures : Number of Patients With Overall Tumor Response [ Time Frame: randomization and every 3 months up to 2 years of post-study followup ] Progression-Free Survival [ Time Frame: baseline to measured progressive disease up to 2057 days ] Overall Survival [ Time Frame: baseline to date of death from any cause up to 2057 days ] Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization [ Time Frame: baseline to 3 months after last dose of study

2005 Clinical Trials

483. S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

OR Zubrod performance status 2 with no co-morbidities or meeting 1 of the following criteria: No co-morbidities FEV_1 < 2 L OR < 1 L with estimated contralateral FEV_1 ≥ 0.6 L DLCO > 10 mL/mm Hg/min Albumin < 0.85 times lower limit of normal Unintentional weight loss > 10% within the past 6 months Controlled congestive heart failure which, in the opinion of the investigator, may become decompensated due to radiotherapy FEV_1 < 2 L OR < 1 L with estimated contralateral FEV_1 ≥ 0.6 L Absolute neutrophil (...) form the date of enrollment until the date of death due to any cause. Patients last known to be alive are censored at the date of last contact. Progression-free Survival. [ Time Frame: At week 10, week 22, and then every 3 months until progression for up to 3 years after enrollment. ] Duration from the date of enrollment until the date of progression (as defined by RECIST: >= 20% increase over baseline in the sum of longest diameters, or appearance of new lesions, or non-measurable disease

2006 Clinical Trials

484. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. (PubMed)

)) relationship. We investigated the impact of recombinant human GH (rhGH) treatment on a-vO(2) difference and the Q-VO(2) relationship during submaximal exercise by randomizing 12 HIV-infected patients (mean +/- sem: age, 43.3 +/- 1.5 yr; body mass, 69.5 +/- 2.9 kg; body mass index, 22.4 +/- 0.9 kg/m(2); maximum oxygen consumption, 33.6 +/- 1.5 ml/kg x min), with documented unintentional weight loss (>or=10% within the preceding 12 months) despite antiretroviral therapy, to receive 3 months of rhGH (6 mg/d (...) Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. The arteriovenous oxygen difference (a-vO(2) difference), a measure of peripheral muscle oxygen extraction-utilization during exercise, is reduced in antiretroviral-treated patients with human immunodeficiency virus (HIV), thus causing a shift in the cardiac output-oxygen consumption (Q-VO(2

Full Text available with Trip Pro

2004 The Journal of clinical endocrinology and metabolism

485. Bedside Assessment of Fall Risk in Emergency Department Elders

in order to find out how predictive the balance tests are in determining the risk of future falls. Condition or disease Accidental Falls Detailed Description: Falls are one of the most significant health risks to older Americans. In the U.S., 30-60% of community dwelling elders will fall each year.Studies have found rates of serious injury among elders who fall to range from 5-24%. Five percent of those who fall are hospitalized. Among elders, falls cause 2/3 of the deaths due to unintentional injury (...) , the 6th leading cause of death in this age group. Additional major morbidity due to falls includes loss of independence as well as anxiety due to fear of falling. This results in limitation of function and often in a requirement for long-term care. Up to 40% of nursing home admissions are due to falls or fear of falling. Expenditures for fall-related injuries account for 6% of all medical expenditures in geriatric patients. Several interventions have been proven effective to reduce rates of fall

2007 Clinical Trials

486. Ghrelin in Older Women

" will increase levels of growth hormone in the blood and increase appetite. Ghrelin is a naturally occurring hormone that is produced mostly by the stomach and causes secretion of another hormone called growth hormone. It also increases short-term appetite and may lower the amount of inflammation in the body. Some people lose their appetite as they age and have unintentional weight loss. This may be caused by a break in the communication between the stomach and the brain. We are particularly interested (...) Ages Eligible for Study: 70 Years and older (Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Frail group: Women aged 70 or greater Able to give informed consent Undiagnosed weight loss (>5% over the previous year) Two of the following four criteria (from Fried L et al, 2001): low grip strength, slow walking speed, subjective exhaustion, low levels of physical activity Healthy group: Women aged 70 or greater Able to give informed consent

2007 Clinical Trials

487. Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.) Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss Contacts and Locations Go (...) to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7). The purpose of this study is to assess the efficacy of GTx-024 on total body lean mass. Secondary endpoints include but are not limited to assessment of GTx-024 on muscle function, total body weight and total body

2007 Clinical Trials

488. Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

lymph nodes, nodal clusters, or progressive lymphadenopathy; Grade 2 or 3 fatigue, fever >/= 100.5 degrees F, night sweats for > 2 weeks w/o documented infection, presence of weight loss >/= 10% over the preceding 6 months; Progressive lymphocytosis with increase in lymphocyte count of >/= 50% over a 2-month period or an anticipated doubling time of < 6 months. Serum bilirubin less than 2mg/dL, serum creatinine less than 2mg/dL unless abnormality is considered due to CLL by investigator. The Eastern (...) Cooperative Oncology Group (ECOG) Performance Status < 3. Patients must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital. Sexually active women of childbearing potential must use birth control during study in manner that risk of failure is minimized. Prior to study enrollment women of childbearing potential must be advised of importance of avoiding pregnancy during trial and potential risk factors for unintentional

2006 Clinical Trials

489. Gastric outlet obstruction secondary to acid ingestion in children. (PubMed)

between ingestion and the first signs of GOO, weight loss, treatment, complications, duration of hospital stay, and long-term follow-up were reviewed.GOO was not observed in any of the children admitted for alkaline ingestion, whereas GOO developed in 8 of 98 children (8.2%) in a mean period of 26.7 +/- 10 days after the ingestion of acid substances. Presenting symptoms were frequent nonbilious vomiting and marked weight loss. All had pyloric obstructions in the upper gastrointestinal series (...) Gastric outlet obstruction secondary to acid ingestion in children. Gastric outlet obstruction (GOO) is a well-known complication of acid ingestion. However, most reports deal with adults. In this report, the authors present their experience with the treatment of acid-induced GOO in children.The records of patients admitted for unintentional ingestion of corrosive agents between 1980 and 2002 were reviewed retrospectively. Data concerning age at ingestion, type of ingested substance, time

2004 Journal of Pediatric Surgery

490. Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3

sample. Have at least one of the following: Oral candidiasis. Herpes zoster during the last 3 years. Oral hairy leukoplakia during the past three years. Chronic ( > 30 day period), recurrent seborrheic dermatitis, or topical, pruritic folliculitis (itchy bumps). Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight. Chronic fatigue present for the past 6 months, which has interfered with normal activity at least 1 to 2 times per week. HIV antibody positive as determined (...) with the exception of Zidovudine. Cancer chemotherapeutic agents. Anti-metabolites and alkylating agents. All investigational non-FDA approved drugs. Patients with the following are excluded: Clinically significant diarrhea (> 3 liquid stools per day for > 7 days) without definable cause, within 6 months prior to enrollment). Diarrhea, as above, with known, non-HIV related cause occurring within one month prior to enrollment. Meets CDC criteria for AIDS classification. Chronic fever (> 38.5 C persisting for more

1999 Clinical Trials

491. A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia

to entry. Unexplained diarrhea defined as three or more liquid stools per day, persisting more than 7 days within 2 years prior to entry. Unintentional weight loss of greater than 10 lbs. or more than 10 percent of usual body weight within 2 years prior to study entry. Oral hairy leukoplakia at any time prior to entry. Oral candidiasis unrelated to the use of antibiotic therapy for more than 2 weeks within 2 years prior to entry or within the past 3 months. Herpes zoster within 2 years prior to entry (...) candidiasis, and localized cutaneous herpes simplex or zoster infections. Probenecid. Aspirin on a regular basis, or for more than 72 hours without contacting the investigator. Drugs causing neutropenia or significant risk of nephrotoxicity. Patients in Study A with the following prior conditions are excluded: AIDS-defining opportunistic infection or malignancy. Unexplained temperature greater than 38 C for more than 5 consecutive days or more than 10 days in any 30-day period in the 2 years prior

1999 Clinical Trials

492. A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS

. Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight). History of sensitivity to the study medication. Malignancies requiring the use of cytotoxic chemotherapy. Coma. Diffuse central white matter lesions. Negative serology for Toxoplasma as performed at the Palo Alto Medical Foundation (unless biopsy is positive). Lymphoma of the central nervous system. Cerebral Kaposi's sarcoma. Hemorrhagic diathesis (...) patients with AIDS. Toxoplasmic encephalitis (encephalitis caused by Toxoplasma gondii) is the most frequent cause of focal central nervous system infection in patients with AIDS. If untreated, the encephalitis is fatal. At present, it is standard practice to give a combination of pyrimethamine and sulfadiazine to treat toxoplasmic encephalitis. The high frequency of sulfonamide-induced toxicity in AIDS patients often makes completion of a full course of therapy difficult. There is some information

1999 Clinical Trials

493. A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

maintenance. Required: Stable prescribed dose of zidovudine (AZT) of at least 500 mg/day. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Prior history of toxoplasmic encephalitis. Unable to take oral medication reliably or have a malabsorption syndrome (i.e., 3 or more loose stools/day for at least 4 weeks associated with an unintentional weight loss of = or > 10 percent of body weight). History of sensitivity to the study medications. Concurrent (...) the development of toxoplasmosis in AIDS patients or delay the subsequent return of toxoplasmic encephalitis. Encephalitis caused by Toxoplasma gondii has emerged as the most frequent cause of focal central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal. The best treatment for this disease has not been determined. Presently it is standard practice to administer a combination of pyrimethamine and sulfadiazine. Little is known about the pharmacokinetics of pyrimethamine

1999 Clinical Trials

494. Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism. (PubMed)

strength. After adjusting for age, race, body height, and weight, the RR of CVD mortality decreased to 2.17 (95% CI = 1.26-3.73) in the lowest and 1.56 (95% CI = 0.89-2.71) in the middle, with the highest grip-strength tertile as the reference. Further adjustments for multiple diseases, physical inactivity, smoking, interleukin-6, C-reactive protein, serum albumin, unintentional weight loss, and depressive symptoms did not materially change the risk estimates. Similar results were observed for all (...) Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism. To examine the association between muscle strength and total and cause-specific mortality and the plausible contributing factors to this association, such as presence of diseases commonly underlying mortality, inflammation, nutritional deficiency, physical inactivity, smoking, and depression.Prospective population-based cohort study with mortality surveillance over 5 years.Elderly women

2003 Journal of the American Geriatrics Society

495. Trying to lose weight, losing weight, and 9-year mortality in overweight U.S. adults with diabetes. (PubMed)

have a reduced risk of all-cause mortality, independent of whether they lose weight. Actual weight loss is associated with increased mortality only if the weight loss is unintentional. (...) Trying to lose weight, losing weight, and 9-year mortality in overweight U.S. adults with diabetes. The aim of this study was to examine the relationships between intention to lose weight, actual weight loss, and all-cause mortality among overweight individuals with diabetes.We performed a prospective analysis among 1,401 overweight diabetic adults aged > or =35 years sampled in the National Health Interview Survey. The previous year intention to lose weight and weight change were assessed

2004 Diabetes Care

496. Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. (PubMed)

(CI, 0.65 to 1.37); and lost weight, 0.76 (CI, 0.60 to 0.97).Attempted weight loss is associated with lower all-cause mortality, independent of weight change. Self-reported intentional weight loss is associated with lower mortality rates, and weight loss is associated with higher mortality rates only if it is unintentional. (...) Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Although weight loss improves risk factors for cardiovascular and metabolic disease, it is unclear whether intentional weight loss reduces mortality rates.To examine the relationships among intention to lose weight, weight loss, and all-cause mortality.Prospective cohort study using a probability sample of the U.S. population.Interviewer-administered survey.6391 overweight and obese persons (body

2003 Annals of Internal Medicine

497. Intentional weight loss, blood lipids and coronary morbidity and mortality. (PubMed)

is associated with increased cardiovascular morbidity and mortality. Recent studies suggest that this association may arise from the confounding effect of preexisting disease. Many studies do not report whether weight loss is intentional or unintentional. Unintentional weight loss may mask beneficial changes in cardiovascular risk due to intentional weight loss. In addition to issues related to the cause of weight loss, use of reported rather than measured weight may bias the results of large studies (...) Intentional weight loss, blood lipids and coronary morbidity and mortality. Although weight reduction has been recommended to reduce cardiovascular risk, studies on the association between weight loss and coronary morbidity and mortality show conflicting results. This review summarizes findings from large studies examining this issue and accentuates the importance of carrying out additional well-designed research.Many observational studies report that weight loss in older men and women

2005 Current Opinion in Lipidology

498. Intentional weight loss was associated with lower mortality, whereas unintentional weight loss was associated with increased mortality

mortality Article Text Causation Intentional weight loss was associated with lower mortality, whereas unintentional weight loss was associated with increased mortality Free Sharon Wong , RD, MSc , Donna Ciliska , RN, PhD Statistics from Altmetric.com Gregg EW, Gerzoff RB, Thompson TJ, et al. Intentional weight loss and death in overweight and obese U.S. adults 35 years of age and older. Ann Intern Med 2003 ; 138 : 383 –9 QUESTION: Are weight change and intention to lose weight associated with all cause (...) up, 892 participants (14%) died. Compared with participants not trying to lose weight and reporting no weight change, all cause mortality was lower in participants with an intention to lose weight, independent of actual weight change but was higher in participants with unintentional weight loss (table ). View this table: Hazard ratios for all cause mortality by weight loss intent and actual weight loss Conclusion In adults who were overweight or obese, intention to lose weight was associated

Full Text available with Trip Pro

2004 Evidence-Based Nursing

499. An approach to the management of unintentional weight loss in elderly people. (PubMed)

to weight loss, but there may be no identifiable cause in up to one-quarter of patients. We review the incidence and prevalence of weight loss in elderly patients, its impact on morbidity and mortality, the common causes of unintentional weight loss and a clinical approach to diagnosis. Screening tools to detect malnutrition are highlighted, and nonpharmacologic and pharmacologic strategies to minimize or reverse weight loss in older adults are discussed. (...) An approach to the management of unintentional weight loss in elderly people. Unintentional weight loss, or the involuntary decline in total body weight over time, is common among elderly people who live at home. Weight loss in elderly people can have a deleterious effect on the ability to function and on quality of life and is associated with an increase in mortality over a 12-month period. A variety of physical, psychological and social conditions, along with age-related changes, can lead

Full Text available with Trip Pro

2005 Canadian Medical Association Journal

500. Reasons for intentional weight loss, unintentional weight loss, and mortality in older men. (PubMed)

Reasons for intentional weight loss, unintentional weight loss, and mortality in older men. We have examined the relationship between intentional and unintentional weight loss and the reasons underlying intention to lose weight and all-cause mortality and mortality due to cardiovascular disease (CVD) and non-CVD causes in older men.Prospective study of 4869 men aged 56 to 75 years drawn from general practices in 24 British towns, who in 1996 completed questionnaires about intentional (...) and unintentional weight loss over the preceding 4 years and were followed up for a subsequent 7 years.Unintentional but not intentional weight loss was associated with a significant increase in risk of all-cause mortality compared with men who reported no weight change, even after adjustment for lifestyle characteristics and preexisting disease (adjusted relative risk [RR], 1.71; 95% confidence interval [CI], 1.33-2.19; and RR, 1.00; 95% CI, 0.91-1.10, respectively). Men who lost weight intentionally

Full Text available with Trip Pro

2005 Archives of Internal Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>